Short Interest Update on Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA) : 5 days before expiry, shorts in Vanda Pharmaceuticals (VNDA) have reduced from 3,044,123 on Jul 29, 2016, to 2,647,162 on August 15, 2016. On an average, 554,001 shares are traded on the exchange. The outstanding bearish positions are equal to 6.3% of the float. Short sellers have covered -396,961 shares, a reduction of -13%, which underlines that they dont expect the stock to fall further from the current levels. The short interest information was released on Wednesday Aug 24th after the market close.

Vanda Pharmaceuticals (NASDAQ:VNDA): The stock opened at $12.32 on Wednesday but the bulls could not build on the opening and the stock topped out at $12.54 for the day. The stock traded down to $11.66 during the day, due to lack of any buying support eventually closed down at $11.75 with a loss of -4.08% for the day. The stock had closed at $12.25 on the previous day. The total traded volume was 547,480 shares.


In a related news, Kelly James Patrick, officer (SVP, CFO, Sec & Treasurer) of Vanda Pharmaceuticals Inc., unloaded 9,564 shares at an average price of $8.96 on January 4, 2016. The total amount of the transaction was worth $85,693, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Companys product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. HETLIOZ (tasimelteon) is a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) for which a New Drug Application (NDA) was approved by the United States Food and Drug Administration (FDA). Fanapt (iloperidone) is a product for the treatment of schizophrenia. Tradipitant (VLY-686) is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is under clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *